Eisai Inc.

This phase 2 trial tests BB-1701, a drug that targets HER2 on breast cancer cells, in 56 people with advanced breast cancer that is HER2-positive or HER2-low. The study has two parts: first to find the best dose, then to see how well it shrinks tumors. Participants receive the dr…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …

This study tested an experimental drug called lecanemab (BAN2401) in 856 people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia. Participants received different doses of the drug or a placebo every 2 or 4 weeks for 18 months. The go…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…